Related Experiment Video

Updated: May 26, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis

Won Oak Kim1, Bon Nyeo Koo, Yong Kook Kim

  • 1Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Korean Journal of Anesthesiology
|December 8, 2011
PubMed
Abstract

Insights

Ramosetron effectively prevents postoperative nausea and vomiting (PONV) in adults and children. This review of randomized controlled trials confirms its safety and efficacy compared to placebo and other drugs.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Postoperative nausea and vomiting (PONV) presents a significant clinical challenge.
  • Existing prophylactic interventions for PONV require ongoing evaluation.
  • Ramosetron is a potential agent for PONV prevention.

Purpose of the Study:

  • To systematically review the efficacy of ramosetron for PONV prevention.
  • To assess the safety profile of ramosetron in randomized controlled trials (RCTs).
  • To compare ramosetron with placebo and other antiemetic drugs.

Main Methods:

  • Conducted a comprehensive literature search across MEDLINE, SCOPUS, and Cochrane databases.
  • Included 18 randomized controlled trials (RCTs) evaluating ramosetron for PONV.
  • Analyzed dichotomous data for PONV prevention and adverse effects.

Main Results:

  • Ramosetron (0.3 mg) demonstrated significant efficacy in preventing early postoperative nausea (PON) and early/late postoperative vomiting (POV).
  • Overall PONV prevention was consistently beneficial for adults and children.
  • Ramosetron showed comparable efficacy to granisetron with no increased adverse events versus placebo.

Conclusions:

  • Ramosetron is an effective and safe option for PONV prevention in both pediatric and adult populations.
  • Pooled RCT data support the use of ramosetron without significant adverse effects.
  • Ramosetron offers a favorable risk-benefit profile for PONV prophylaxis.
Keywords:
AntiemeticsMeta-analysisPONVRamosetron

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...